HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs

Int J Cardiol. 2014 Oct 20;176(3):1082-5. doi: 10.1016/j.ijcard.2014.07.129. Epub 2014 Aug 2.
No abstract available

Keywords: Cancer chemotherapy; Cardio-oncology; Cardiotoxicity; HERG; Multidrug resistance (MDR); Torsade de pointes arrhythmia(TdP).

Publication types

  • Letter
  • Review

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
  • Animals
  • Cardiovascular Agents / administration & dosage*
  • Cardiovascular Agents / metabolism
  • Cardiovascular System / drug effects*
  • Cardiovascular System / metabolism
  • ERG1 Potassium Channel
  • Ether-A-Go-Go Potassium Channels / antagonists & inhibitors*
  • Ether-A-Go-Go Potassium Channels / metabolism
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Cardiovascular Agents
  • ERG1 Potassium Channel
  • Ether-A-Go-Go Potassium Channels
  • KCNH2 protein, human